Disc Medicine Inc
NASDAQ:IRON
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (19.1), the stock would be worth $-107.12 (262% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -11.8 | $65.95 |
0%
|
| Industry Average | 19.1 | $-107.12 |
-262%
|
| Country Average | 22.9 | $-128.06 |
-294%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
$2.5B
|
/ |
Jan 2026
$-212.2m
|
= |
|
|
$2.5B
|
/ |
Dec 2026
$-278.6m
|
= |
|
|
$2.5B
|
/ |
Dec 2027
$-293.8m
|
= |
|
|
$2.5B
|
/ |
Dec 2028
$-234.3m
|
= |
|
|
$2.5B
|
/ |
Dec 2029
$-118.7m
|
= |
|
|
$2.5B
|
/ |
Dec 2030
$64m
|
= |
|
|
$2.5B
|
/ |
Dec 2031
$294.3m
|
= |
|
|
$2.5B
|
/ |
Dec 2032
$375.1m
|
= |
|
|
$2.5B
|
/ |
Dec 2033
$462m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Disc Medicine Inc
NASDAQ:IRON
|
2.5B USD | -11.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 89.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 19.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 27.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 16.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 29.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.3 |
| Median | 22.9 |
| 70th Percentile | 33.2 |
| Max | 1 826 183.3 |
Other Multiples
Disc Medicine Inc
Glance View
Disc Medicine Inc., a biopharmaceutical company, is carving its niche in the healthcare landscape through its innovative approach to addressing hematologic disorders. Founded with a vision to revolutionize treatments for blood-related diseases, Disc Medicine focuses on developing novel, first-in-class therapies that target heme biosynthesis pathways. By tackling the underlying causes of various blood disorders rather than just managing symptoms, the company is poised to offer groundbreaking solutions in treating conditions that have long baffled the medical community. The company's research-driven ethos is supported by a robust pipeline of drug candidates, each underpinned by strong scientific rigor and a commitment to patient-centric outcomes. The business model of Disc Medicine revolves around creating value through its unique intellectual property and proprietary technology. Leveraging strategic partnerships and collaborations with leading academic and research institutions, Disc Medicine aims to accelerate the development and commercialization of its therapies. Revenue streams are anticipated to flow through successful drug approvals and subsequent market penetration, with potential licensing agreements further augmenting its financial standing. This intricate interplay of innovation, collaboration, and strategic foresight positions Disc Medicine as a promising player in the ever-evolving biopharmaceutical industry, steadfast in its mission to transform the treatment landscape for patients with hematologic disorders.
